Highlights:
- Allkem reported a rise in cash on a quarterly basis.
- The group revenue stood at AU$298 million in the September quarter.
- Lithium carbonate sales generated a revenue of nearly US$150 million during the quarter.
Allkem Limited (ASX:AKE) on Friday (21 October 2022) released its quarterly activities report for the period ending on 30 September 2022. Through an ASX filling, the lithium explorer has provided an update about its global lithium portfolio, financial position and business activities.
Following the update, Allkem’s shares were spotted trading 3.82% lower at AU$14.35 per share at 11:29 AM AEDT. In the past one month, Allkem’s share price has dropped by 8.49%. The yearly gain stands at 58.98% and on a year-to-date (YTD) basis, the stock price has increased by 28.04%. In the past five years, the share price has zoomed up by 204.46%.
Meanwhile, the benchmark index, ASX 200 Materials (INDEXASX:XMJ) was 0.19% to 15,423.60 points at 11:55 AM AEDT.
Key highlights of the quarterly update
- Production at the Olaroz Lithium facility increased by 17% on prior corresponding period (pcp).
- The company reported lithium carbonate sales of 3,721 tonnes during the quarter which generated revenue of circa US$150 million.
- The group revenue in three months was AU$298 million.
- The gross operating cash margin was 82%.
- Net cash at the end of the quarter was US$447 million.
Allkem’s expectations
- Allkem expects the weighted average price for third-party sales of lithium carbonate products in the next quarter to be approximately 15% higher than this quarter.
- In the December quarter, the company expects to see spodumene concentrate pricing be in line with the September quarter.
- At Olaroz Stage 2, the capital expenditure is expected to increase by around 12%, excluding working capital and VAT. Reportedly, it will be funded via operating cashflows.
- At Naraha, the first production is expected in the December quarter.
- The company expects Olaroz Stage 2 production during the first half of 2023.
- Sal De Vida is anticipated to begin production in late 2023. Production at James Bay is expected in mid-2024.
- The forecasted production at Mt Cattlin for FY23 was revised in late August to 140kt-150kt of spodumene concentrate because of equipment and ongoing labour shortage.